急性与亚急性非复杂性B型主动脉夹层腔内修复与药物治疗的比较
基于TriNetX网络2007至2019年数据,20,376例非复杂性B型主动脉夹层患者中,18,840例(92.5%)接受药物治疗,急性期TEVAR组1,099例(5.4%),亚急性期TEVAR组437例(2.1%)。倾向匹配后,急性期TEVAR组3年生存率低于药物治疗组,亚急性期TEVAR组3年生存率与药物治疗组无显著差异但3年内镜再干预率显著更高;亚急性期TEVAR组3年生存率高于急性期TEVAR组且3年破裂率更低。
要点
- 急性期TEVAR组3年生存率86.6% vs 药物治疗组83.3%(P=.041),急性期TEVAR组更低。
- 亚急性期TEVAR组3年内镜再干预率12.6% vs 药物治疗组7.8%(P=.019),亚急性期TEVAR组显著更高。
- 亚急性期TEVAR组3年生存率88.5% vs 急性期TEVAR组84.0%(P=.039),亚急性期TEVAR组更高。
核心结论
- 急性期TEVAR组3年生存率低于药物治疗组;亚急性期TEVAR组与药物治疗组相比未发现3年生存获益,作者认为需进一步研究非复杂性B型主动脉夹层TEVAR与药物治疗的必要性,因TEVAR不劣于药物治疗。
- 亚急性期TEVAR组3年生存率高于急性期TEVAR组且3年破裂率更低,作者认为提示亚急性期TEVAR更优。
- 作者提出需进一步研究以确定急性非复杂性B型主动脉夹层TEVAR的长期获益和最佳时机。
研究设计与样本
- 利用TriNetX网络识别2007年至2019年间非复杂性B型主动脉夹层患者,按治疗类型分为药物治疗组、急性期(1至14天)TEVAR组和亚急性期(2周至3个月)TEVAR组。
- 倾向匹配后分析死亡率、内镜再干预和破裂等结局。
主要发现
- 20,376例非复杂性B型主动脉夹层患者中,药物治疗18,840例(92.5%),急性期TEVAR组1,099例(5.4%),亚急性期TEVAR组437例(2.1%)。
- 与药物治疗相比,急性期TEVAR组30天和3年破裂率更高(4.1% vs 1.5%;P<.001;9.9% vs 3.6%;P<.001),3年内镜再干预率更高(7.6% vs 1.6%;P<.001),30天死亡率相似(4.4% vs 2.9%;P=.068),3年生存率更低(86.6% vs 83.3%;P=.041)。
- 与药物治疗相比,亚急性期TEVAR组30天死亡率(2.3% vs 2.3%;P=1)、3年生存率(87.0% vs 88.8%;P=.377)及30天和3年破裂率(2.3% vs 2.3%;P=1;4.6% vs 3.4%;P=.388)相似,3年内镜再干预率显著更高(12.6% vs 7.8%;P=.019)。
- 与亚急性期TEVAR组相比,急性期TEVAR组30天死亡率(4.2% vs 2.5%;P=.171)、破裂率(3.0% vs 2.5%;P=.666)和3年内镜再干预率(12.6% vs 10.6%;P=.380)相似,3年破裂率显著更高(8.7% vs 3.5%;P=.002)。
- 亚急性期TEVAR组3年生存率显著高于急性期TEVAR组(88.5% vs 84.0%;P=.039)。
临床怎么用
- 作者认为,对于非复杂性B型主动脉夹层,亚急性期TEVAR与药物治疗相比未发现3年生存获益,需进一步研究TEVAR的必要性。
- 作者认为,与急性期TEVAR相比,亚急性期TEVAR的3年生存率更高且3年破裂率更低,提示亚急性期TEVAR更优。
- 作者提出需进一步研究以确定急性非复杂性B型主动脉夹层TEVAR的长期获益和最佳时机。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) has emerged as a viable option of treatment for uncomplicated type B aortic dissection (UTBAD) due to the potential for inducing favorable aortic remodeling. The aim of this study is to compare outcomes of UTBAD treated medically or with TEVAR in either the acute (1 to 14 days) or subacute period (2 weeks to 3 months). METHODS: Patients with UTBAD between 2007 and 2019 were identified using the TriNetX Network. The cohort was stratified by treatment type (medical management; TEVAR during the acute period; TEVAR during the subacute period). Outcomes including mortality, endovascular reintervention, and rupture were analyzed after propensity matching. RESULTS: Among 20,376 patients with UTBAD, 18,840 were medically managed (92.5%), 1099 patients were in the acute TEVAR group (5.4%), and 437 patients were in the subacute TEVAR group (2.1%). The acute TEVAR group had higher rates of 30-day and 3-year rupture (4.1% vs 1.5%; P < .001; 9.9% vs 3.6%; P < .001) and 3-year endovascular reintervention (7.6% vs 1.6%; P < .001), similar 30-day mortality (4.4% vs 2.9%; P < .068), and lower 3-year survival compared with medical management (86.6% vs 83.3%; P = .041). The subacute TEVAR group had similar rates of 30-day mortality (2.3% vs 2.3%; P = 1), 3-year survival (87.0% vs 88.8%; P = .377) and 30-day and 3-year rupture (2.3% vs 2.3%; P = 1; 4.6% vs 3.4%; P = .388), with significantly higher rates of 3-year endovascular reintervention (12.6% vs 7.8%; P = .019) compared with medical management. The acute TEVAR group had similar rates of 30-day mortality (4.2% vs 2.5%; P = .171), rupture (3.0% vs 2.5%; P = .666), significantly higher rates of 3-year rupture (8.7% vs 3.5%; P = .002), and similar rates of 3-year endovascular reintervention (12.6% vs 10.6%; P = .380) compared with the subacute TEVAR group. There was significantly higher 3-year survival (88.5% vs 84.0%; P = .039) in the subacute TEVAR group compared with the acute TEVAR group. CONCLUSIONS: Our results found lower 3-year survival in the acute TEVAR group compared with the medical management group. There was no 3-year survival benefit found in patients with UTBAD who underwent subacute TEVAR compared with medical management. This suggests the need for further studies looking at the necessity for TEVAR when compared with medical management for UTBAD as it is non-inferior to medical management. Higher rates of 3-year survival and lower rates of 3-year rupture in the subacute TEVAR group compared with the acute TEVAR group suggest superiority of subacute TEVAR. Further investigations are needed to determine the long-term benefit and optimal timing of TEVAR for acute UTBAD.
引用
- Muller M, Yau P, Pham A, et al. A comparison of endovascular repair to medical management for acute vs subacute uncomplicated type B aortic dissections. J Vasc Surg. 2023. PMID: 36889606. doi:10.1016/j.jvs.2023.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。